Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Real World Evaluation of Ciltacabtagene Autoleucel (cilta-cel) Toxicity Management: A Single Center Experience | Synapse
March 3, 2026
Real World Evaluation of Ciltacabtagene Autoleucel (cilta-cel) Toxicity Management: A Single Center Experience
JM
Jessica Marini
Medical University of South Carolina
MM
Mary McGann
Medical University of South Carolina
KG
Katelynn Granger
Medical University of South Carolina
Ver todo
Puntos clave
Ciltacabtagene autoleucel treatment is associated with manageable toxicities, and patients show resilient immune responses.
Observed outcomes include low adverse events, suggesting ciltacabtagene autoleucel is safe for wider application.
Single center assessment emphasizes the importance of toxicity management protocols to ensure patient safety.
Management strategies warrant further evaluation across diverse patient populations to enhance treatment efficacy.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Marini et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760d9c6e9836116a2dfbf
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.938
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir